Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 long-term safety, tolerability, and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder: A randomized, active comparator-controlled trial.

Next Previous
Trial Profile

Phase 3 long-term safety, tolerability, and effectiveness of lurasidone in subjects with schizophrenia or schizoaffective disorder: A randomized, active comparator-controlled trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary) ; Risperidone
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Sumitomo Pharma America

Most Recent Events

  • 20 Sep 2016 Results of post hoc analysis from this and Pearl-3 study (Profile 234648), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
  • 31 Mar 2015 Post-hoc analysis of pooled data from this and another phase III trial (CT profile 700234648) presented at the 23rd European Congress of Psychiatry (EPA) 2016, according to a Sunovian Pharmaceuticals media release.
  • 21 Oct 2014 Post hoc analysis comparing the effect of lurasidone versus risperidone on metabolic syndrome status in patients with schizophrenia presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top